Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Anna M. Varghese

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5426-0885; OpenAlex author ID A5027467209. Sources: OpenAlex.

Their work

Papers
33 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
105
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: 4 papers · 2019: 1 paper · 2020: 2 papers · 2021: 4 papers · 2022: 4 papers · 2023: 2 papers · 2024: 3 papers · 2025: 6 papers · 2026: 4 papers

Papers 33

  1. Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2026.2988↗
  2. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  3. A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-25-3189↗
  4. POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer Co-author DOI 10.64898/2026.03.15.711961↗
  5. Nonoperative Management of Technically Resectable Pancreatic Cancer With Ablative Radiation Therapy. Co-author DOI 10.1001/jamaoncol.2025.0460↗
  6. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08508-4↗
  7. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Co-author DOI 10.1038/s41591-024-03362-3↗
  8. Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. Co-author DOI 10.1093/jnci/djae269↗
  9. Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf139↗
  10. Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer. Co-author DOI 10.1200/op-24-00528↗
  11. Morbidity and mortality in patients with stage IV pancreatic adenocarcinoma and acute cholangitis: Outcomes and risk prognostication. Co-author DOI 10.1016/j.pan.2024.05.515↗
  12. Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease. Co-author DOI 10.1093/jnci/djae095↗
  13. Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery. Co-author DOI 10.3390/jcm13092631↗
  14. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06063-y↗
  15. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-3089↗
  16. Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer. Co-author DOI 10.1002/cncr.34269↗
  17. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.26735↗
  18. Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s40291-022-00614-1↗
  19. Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system. Co-author DOI 10.1016/j.phro.2022.10.003↗
  20. Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. Co-author DOI 10.1001/jamaoncol.2021.0057↗
  21. Treatment patterns and survival in patients with early-onset pancreatic cancer. Co-author DOI 10.1002/cncr.33664↗
  22. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. Co-author DOI 10.1097/sla.0000000000005080↗
  23. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. Co-author DOI 10.1136/jitc-2020-002068↗
  24. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.33038↗
  25. Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41379-020-0549-5↗
  26. Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review. Co-author DOI 10.1016/j.ctrv.2019.03.003↗
  27. Visceral Thromboses in Pancreas Adenocarcinoma: Systematic Review. Co-author DOI 10.1016/j.clcc.2017.12.001↗
  28. Incidence, Management, and Implications of Visceral Thrombosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.clcc.2018.01.008↗
  29. Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Co-author DOI 10.1158/1078-0432.ccr-17-3099↗
  30. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. Co-author DOI 10.1186/s12885-018-4605-1↗
  31. CAR T-cell therapy for pancreatic cancer. Co-author DOI 10.1002/jso.24627↗
  32. Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Co-author DOI 10.1158/1078-0432.ccr-17-0899↗
  33. Current management and future directions in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.30342↗

Closest collaborators

The 25 strongest of 105 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Eileen Mary O'Reilly · 29 shared papers, 2016–2026 · strength 3.97
  2. Kenneth H. Yu · 24 shared papers, 2016–2026 · strength 3.24
  3. Wungki Park · 18 shared papers, 2019–2026 · strength 2.81
  4. Alice Chia-Chi Wei · 12 shared papers, 2021–2026 · strength 1.96
  5. William R. Jarnagin · 12 shared papers, 2017–2026 · strength 1.73
  6. Jeffrey A. Drebin · 10 shared papers, 2020–2026 · strength 1.51
  7. Marinela Capanu · 10 shared papers, 2018–2026 · strength 1.45
  8. Kevin C. Soares · 9 shared papers, 2021–2026 · strength 1.44
  9. Michael Ian D'Angelica · 9 shared papers, 2020–2026 · strength 1.34
  10. Christopher H. Crane · 8 shared papers, 2021–2026 · strength 1.26
  11. Vinod P. Balachandran · 9 shared papers, 2017–2026 · strength 1.24
  12. T. Peter Kingham · 8 shared papers, 2020–2025 · strength 1.12
  13. Fiyinfolu O. Balogun · 6 shared papers, 2024–2026 · strength 1.11
  14. Danny N. Khalil · 6 shared papers, 2021–2026 · strength 1.02
  15. Marsha Reyngold · 6 shared papers, 2021–2026 · strength 0.94
  16. Fergus Keane · 5 shared papers, 2024–2026 · strength 0.89
  17. Christine A. Iacobuzio–Donahue · 7 shared papers, 2017–2026 · strength 0.80
  18. Carla Hajj · 4 shared papers, 2021–2026 · strength 0.70
  19. Olca Baştürk · 5 shared papers, 2017–2026 · strength 0.66
  20. Abraham Jing-Ching Wu · 4 shared papers, 2021–2025 · strength 0.62
  21. David Paul Kelsen · 5 shared papers, 2018–2025 · strength 0.61
  22. Mark Andrew Schattner · 4 shared papers, 2017–2026 · strength 0.61
  23. Darren Cowzer · 3 shared papers, 2024–2025 · strength 0.53
  24. Anupriya Singhal · 3 shared papers, 2024–2025 · strength 0.53
  25. Caitlin A. McIntyre · 4 shared papers, 2020–2026 · strength 0.50

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.